Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATLCAR.CD30 cells | CAR.CD30-expressing autologous T lymphocytes | ATLCAR.CD30 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets TNFRSF8 (CD30), which may induce lysis of TNFRSF8 (CD30)-positive tumor cells (PMID: 32701411, NCI Drug Dictionary). | ||
ATLCAR.CD30.CCR4 cells | ATLCAR.CD30-CD28zeta-CCR4 cells | ATLCAR.CD30.CCR4 cells are autologous T-lymphocytes engineered to express CCR4 linked to a chimeric antigen receptor (CAR) targeting CD30 and the CD28 and CD3zeta co-stimulatory domains, which potentially increase antitumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03602157 | Phase I | ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | Recruiting | USA | 0 |